Jaguar Animal Health (JAGX) AI Stock Analysis

• Market Cap: $3.79M
• Dividend Yield: N/A
• Average Volume (3M): 90.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: 13.93%
• EPS Growth: 91.30%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -16.70
• Shares Outstanding: 1,914,430
• 10 Day Avg. Volume: 87,570
• 30 Day Avg. Volume: 90,186
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.12
• Enterprise Value/Market Cap: 9.58
• Enterprise Value/Revenue: 40.76
• Enterprise Value/Gross Profit: 314.95
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: $3.00
• Price Target Upside: 51.52% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: $2.00 ▲(1.01%Upside)

Jaguar Animal Health's overall stock score is heavily impacted by its poor financial performance, as indicated by high leverage and consistent losses. Technical analysis further underscores a bearish market sentiment. While corporate events and research breakthroughs provide some optimism, they are insufficient to counteract the prevailing financial and technical challenges.

Jaguar Animal Health Business Overview & Revenue Model

Company Description

Jaguar Animal Health, trading under the ticker symbol JAGX, is a biopharmaceutical company focused on developing and commercializing gastrointestinal products for both companion and production animals. The company operates in the animal health and agriculture sectors, with its core products aimed at treating diarrhea and other gastrointestinal conditions in animals, which is a significant issue in veterinary medicine.

How the Company Makes Money

Jaguar Animal Health generates revenue primarily through the sale and licensing of its proprietary products and technologies. The company's revenue streams include direct sales of its gastrointestinal health products to veterinary clinics, distributors, and agricultural enterprises. Additionally, Jaguar seeks to establish partnerships and licensing agreements with other companies in the animal health sector, allowing it to reach wider markets and leverage its research and development capabilities. Key factors contributing to its earnings include the demand for effective treatments for animal gastrointestinal issues, its ability to innovate and bring new products to market, and strategic collaborations within the industry.

Jaguar Animal Health Financial Statement Overview

Summary

Jaguar Animal Health faces substantial financial challenges, characterized by high leverage, consistent net losses, and negative cash flows. The company has high debt levels and negative free cash flow, offset slightly by strong gross margins and some revenue growth.

Income Statement

Jaguar Animal Health has shown a mixed performance with inconsistent revenue growth. The revenue grew by approximately 18.38% from 2023 to 2024 but showed a decline previously. Gross profit margins are reasonably high, but the company struggles with negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a Debt-to-Equity ratio of approximately 5.63 in 2024, reflecting significant reliance on debt financing. The return on equity is negative due to consistent net losses, and the equity ratio is low, suggesting financial instability and potential risks related to excessive debt.

Cash Flow

Cash flow analysis reveals a negative trend in free and operating cash flows, although there was a slight improvement from 2023 to 2024. The company managed to secure significant financing cash flows, which have been covering operational deficits. However, the negative free cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.69M	9.76M	11.96M	4.33M	9.38M
Gross Profit	9.73M	7.72M	9.94M	2.00M	6.11M
EBITDA	-36.66M	-33.13M	-33.38M	-42.35M	-28.74M
Net Income	-38.49M	-41.30M	-47.45M	-60.25M	-36.79M
Balance Sheet
Total Assets	53.42M	50.76M	47.45M	53.27M	42.84M
Cash, Cash Equivalents and Short-Term Investments	8.00M	6.47M	5.47M	17.05M	8.09M
Total Debt	36.53M	37.09M	34.84M	29.36M	16.21M
Total Liabilities	46.93M	45.87M	48.81M	41.41M	25.64M
Stockholders Equity	7.29M	4.96M	-657.00K	11.61M	17.20M
Cash Flow
Free Cash Flow	-29.61M	-33.24M	-34.78M	-34.98M	-15.29M
Operating Cash Flow	-29.38M	-33.24M	-33.10M	-34.97M	-15.28M
Investing Cash Flow	-231.00K	1.23M	-1.68M	-6.00K	-7.00K
Financing Cash Flow	31.20M	34.23M	23.18M	43.94M	19.49M

Jaguar Animal Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.98 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 3.08, and below the 200-day MA of 14.52, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 23.92 is Positive, neither overbought nor oversold. The STOCH value of 8.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.

Jaguar Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.63B	3.88	-56.57%	2.69%	36.37%	13.78%
JAGX	39 Underperform	$3.79M	―	-423.79%	―	13.93%	91.30%
SNGX	39 Underperform	$9.56M	―	-437.73%	―	―	57.83%
SXTP	39 Underperform	$4.32M	―	-181.43%	―	109.29%	-206.99%
GLMD	28 Underperform	$3.50M	―	-49.58%	―	―	71.41%
REVB	28 Underperform	$3.74M	―	-233.26%	―	―	-115.81%
DRMA	15 Underperform	$41.14M	―	-206.26%	―	―	75.68%

Jaguar Animal Health Corporate Events

Jaguar Animal Health Issues Series M Preferred Stock

On June 27, 2025, Jaguar Health, Inc. entered into exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, issuing Series M Preferred Stock in exchange for reductions in outstanding royalty interests. This strategic move allows Jaguar Health to manage its financial obligations while offering stakeholders a structured investment opportunity through the Series M Preferred Stock, which includes specific rights and limitations, impacting the company’s capital structure and market positioning.

Jaguar Animal Health Extends Maturity Date for Notes

On June 24, 2025, Jaguar Health, Inc. announced an extension of the maturity date for $2.57 million of convertible promissory notes from its March 2025 bridge financing, now maturing on January 30, 2026. This extension, involving participation from the company’s CEO, board members, and other investors, aims to support Jaguar’s strategic goals, including partnerships for non-dilutive funding and advancing development programs for crofelemer in treating various conditions.

Jaguar Health Announces $1.5M Direct Stock Offering

On May 20, 2025, Jaguar Health, Inc. entered into a securities purchase agreement for a registered direct offering of 246,306 shares of common stock at $6.09 per share, expected to raise approximately $1.5 million. The offering, set to close around May 22, 2025, includes a concurrent private placement of unregistered warrants to purchase up to 492,612 shares. The proceeds will be used for corporate purposes, including working capital and debt repayment. H.C. Wainwright & Co. acted as the placement agent, receiving a fee and warrants as compensation. This move is part of Jaguar’s strategy to strengthen its financial position and support its operational and development goals.

Jaguar Animal Health Executes Stock Exchange Agreements

On May 13 and 14, 2025, Jaguar Health, Inc. executed several stock exchange agreements to manage its financial obligations. The company issued common and preferred stock to reduce outstanding royalty interests and replace existing preferred stock, impacting its financial structure and shareholder equity. These transactions are part of Jaguar’s broader strategy to optimize its capital structure and potentially improve its market positioning. Additionally, Jaguar reported a decrease in first-quarter 2025 revenue compared to the previous year and quarter, with a notable increase in sales and marketing expenses due to expanded market access activities.

Jaguar Health Highlights Promising Crofelemer Study Results

On May 9, 2025, Jaguar Health released a slide presentation detailing its ongoing efforts to develop and commercialize crofelemer for various indications, including HIV-related diarrhea and short bowel syndrome. Recent studies presented in April 2025 showed promising results for crofelemer in reducing parenteral support in patients with intestinal failure, potentially improving their quality of life. The company is also pursuing additional business development deals and regulatory designations to enhance its market positioning.